Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma – final results from a randomized investigator-initiated trial

View Full Paper
Ask AI
Bookmark
Share

Authors

SDSean DevlinMemorial Sloan Kettering Cancer CenterNKNeha KordeMemorial Sloan Kettering Cancer CenterMSMichael ScordoMemorial Sloan Kettering Cancer Center

Discussion

Loading...

Member takes

Overview

Randomized trial compared daratumumab to lenalidomide maintenance, showing similar quality of life outcomes in patients.

Key Points

  • To evaluate the effects of daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma patients.
  • Single-center open-label randomized study comparing dara and len as maintenance therapy.
  • Participants were NDMM patients achieving ≥VGPR after induction treatment.
  • Follow-up included monthly QOL surveys, serologic markers, imaging, and biopsies.
  • No significant difference in global health status between maintenance therapies (p=0.9).
  • Both groups experienced improvements in various aspects of quality of life over time.
  • Daratumumab showed similar efficacy with higher rates of certain responses compared to lenalidomide, albeit non-significant.

Cite This Study

Devlin et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df45https://doi.org/10.1182/blood-2025-2273
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P22 | WHEN TRIAL DESIGN MEETS APPROVED MAINTENANCE: A SINGLE-CENTER REAL-WORLD EXPERIENCE WITH DARA-VTD INDUCTION AND CONSOLIDATION FOLLOWED BY LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA2026
  2. 2Role of bortezomib maintenance therapy in the anti-CD38 antibody era: Interim analysis results of a randomized Phase III study for transplant-ineligible newly diagnosed multiple myeloma (JCOG1911/B-DASH Study)2025 · 1 citations
  3. 3Clinical outcomes of retreatment with daratumumab-based regimens in anti-CD38 refractory multiple myeloma.2024 · 1 citations
  4. 4Phase 1b study of cyclophosphamide, pomalidomide, dexamethasone, and daratumumab (CPD-DARA) in relapsed/refractory multiple myeloma: Safety and efficacy in a heavily pretreated population2025
  5. 5Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients2024 · 1 citations